Preterm labour: summary of NICE guidance

Grammati Sarri, senior research fellow and guideline lead, Melanie Davies, clinical director, consultant obstetrician and gynaecologist, Maryam Gholitabar, research fellow, and Jane E Norman, chair of Guideline Development Group, professor of maternal and fetal health and director of centre, on behalf of the Guideline Development Group.

Preterm birth is the single biggest cause of neonatal mortality and morbidity in the UK, affecting over 52,000 babies (around 7.3% of live births) in England and Wales in 2012. About 75% of women delivering preterm do so after preterm labour, which is sometimes preceded by preterm prelabour membrane rupture. A “cause” for preterm labour is not always found, but it may be associated with infection. In other cases, preterm birth may result from elective delivery.

Babies born preterm have high rates of mortality, with the risk of mortality being inversely proportional to gestational age at birth. Babies who survive have increased rates of disability.

This article summarises the most recent recommendations on the prevention, diagnosis, and management of preterm labour from the National Institute for Health and Care Excellence (NICE).

Recommendations

NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the Guideline Development Group’s experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.

Information and support for women at risk or at preterm labour (and their family members or carers as appropriate)

- Bear in mind that the woman (and her family members or carers) may be particularly anxious. [Based on moderate to low quality evidence from qualitative studies and the experience and opinion of the Guideline Development Group (GDG)]

- Give information (oral and written) and support as early as possible, taking into account the likelihood of preterm birth and the status of labour. [Based on moderate to low quality evidence from qualitative studies and the experience and opinion of the GDG]

Information and support for women having a planned preterm birth or who are offered treatment for preterm labour (and their family members or carers as appropriate)

- Provide information about the likelihood of the baby surviving and other outcomes (including long term outcomes) and risks for the baby, giving values as natural frequencies (such as 1 in 100).

- Explain about the neonatal care of preterm babies, including location of care.

- Explain about the immediate problems that can arise when a baby is born preterm. [Based on moderate to low quality evidence from qualitative studies and the experience and opinion of the GDG]

Prevention of preterm birth

- Offer a choice of either prophylactic vaginal progesterone or prophylactic cervical cerclage to women with:
  - a history of spontaneous preterm birth or mid-trimester loss between 16 and 34 weeks of pregnancy and
  - a transvaginal ultrasound scan carried out between 16 and 24 weeks of pregnancy showing a cervical length of <25 mm. [Based on high to very low quality evidence from randomised controlled trials]
What you need to know

- To prevent preterm birth, offer a choice of either prophylactic vaginal progesterone or prophylactic cervical cerclage to women with:
  - a history of spontaneous preterm birth or mid-trimester loss between 16th and 24th weeks of pregnancy and
  - a transvaginal ultrasound scan between 16th and 24th weeks of pregnancy, showing a cervical length of <25 mm.
- To diagnose preterm labour:
  - consider transvaginal ultrasound measurement of cervical length to determine likelihood of birth within 48 hours for women who are ≥30th weeks pregnant and are in suspected preterm labour. If cervical length is >15 mm, explain that she is unlikely to be in preterm labour.
- To treat preterm labour:
  - offer tocolysis, corticosteroids, or magnesium sulfate to women in preterm labour, including those with a cervical length of <15 mm, depending on gestation and clinical circumstances.

What’s new in this guidance

- Do not use diagnostic tests for preterm labour for symptomatic women who are <30th weeks pregnant, but treat them as appropriate
- Use cervical length ultrasound for diagnosis of preterm labour for women at ≥30th weeks of pregnancy and treat them as if they are in preterm labour if cervical length is found at ≤15 mm
- Use prophylactic progesterone or cervical cerclage to prevent preterm birth to women with a history of spontaneous preterm birth or mid-trimester loss and cervical ultrasound measurement of <25 mm at 16th to 24th weeks gestation
- For women in established preterm labour or having a planned preterm birth within 24 hours: use magnesium sulfate for neuroprotection between 24th and 28th weeks of pregnancy, and consider its use between 30th and 33rd weeks

Rescue cerclage

- Do not offer “rescue” cervical cerclage to women with signs of infection, active vaginal bleeding, or uterine contractions.
- Consider rescue cervical cerclage for women between 16th and 27th weeks of pregnancy with a dilated cervix and exposed, unruptured fetal membranes.

Fetal monitoring options (cardiotocography and intermittent auscultation)

- For women in preterm labour, discuss:
  - the purpose of fetal monitoring and what it involves
  - the clinical decisions it informs at different gestational ages
  - if appropriate, the option not to monitor the fetal heart rate (for example, at the threshold of viability).

Timing of cord clamping for preterm babies (born vaginally or by caesarean section)

- Wait at least 30 seconds, but no longer than 3 minutes, before clamping the cord of preterm babies if the mother and baby are stable.
Overcoming barriers

This guideline recommends strategies to reduce risks in women who are at high likelihood of preterm delivery. One of the main barriers to the implementation of this guidance is the availability of transvaginal ultrasound scans to diagnose preterm labour, and thus facilitate treatment and transfer to a place where appropriate neonatal intensive care can be provided, a strategy known to improve rates of survival for the baby. There is also currently variation in clinical practice in use of tocolytic agents, uncertainty as to which women will benefit, when it should be given, and the choice of tocolytic. The appropriate use of tocolysis will delay preterm delivery and allow additional antenatal strategies to improve outcomes for babies born preterm.

The members of the Guideline Development Group were: Judi Barratt, Paul Eunson, Jane Hawdon, Jane Norman (chair), Philip Owen, Jane Plumb, Farrah Pradhan, Marianne Rowntree, Meekai To, Martin Ward Platt, and Louise Weaver-Lowe. The members of the National Collaborating Centre for Women’s and Children’s Health technical team were: Grammati Sarri, Melanie Davies (from December 2014), Anne Carty, Maryam Gholitabar, Shona Burman-Roy, Hugo Pedder, Paul Jacklin, and Zosia Beckles.

Contributors: All authors contributed to the initial draft, helped revise the manuscript, and approved the final version for publication. GS is guarantor.

Funding: The National Collaborating Centre for Women’s and Children’s Health was commissioned and funded by the National Institute for Health and Care Excellence to develop this guideline and write this BMJ summary.

We declare the following interests based on NICE’s policy on conflicts of interests (available at www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/code-of-practice-for-declaring-and-managing-conflicts-of-interest.pdf). JN has been remunerated for chairing NICE guideline development committees and has research grants from government bodies and charities to investigate the causes and treatment of preterm birth, including research funding for a large trial of the effect of progesterone on preterm birth prophylaxis. MD receives no direct funding for her advisory or educational roles. The authors’ full statements can be viewed at www.bmj.com/content/bmj/351/bmj.h6283/related#data supp.

Provenance and peer review: Commissioned; not externally peer reviewed.

How patients were involved in the creation of this article

Committee members involved in this guideline included three lay members, who contributed to the formulation of the recommendations summarised here.

Further information on the guidance

This guideline was commissioned with the aim to standardise the care of women in preterm labour and address the knowledge gap regarding the management of preterm labour.

Guidelines into practice

- Audit the requests for diagnostic tests for preterm labour in women presenting with symptoms of preterm labour at ≥30 weeks of pregnancy. Do you need to change your practice by instead treating all symptomatic women who are pregnant <30 weeks as they were diagnosed for preterm labour?
- Audit the prescription of antibiotics for women with preterm prelabour rupture of membranes. Were all women offered antibiotic prophylaxis (erythromycin 250 mg four times a day for a maximum of 10 days)?
- Audit the use of magnesium sulfate for women who are pregnant ≤24 weeks. For women at later gestation and in established preterm labour or having a planned preterm birth within 24 hours, offer magnesium sulfate only if between 24\(^\text{th}\) and 29\(^\text{th}\) weeks pregnant; consider its use if between 30 and 33\(^\text{rd}\) weeks pregnant.

Methods

This guidance was developed by the National Collaborating Centre for Women’s and Children’s Health in accordance with NICE guideline development methods (www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf). A Guideline Development Group was established by the National Collaborating Centre for Women’s and Children’s Health, which incorporated healthcare professionals (including obstetricians and gynaecologists, midwives, neonatal nurses, and neonatologists) and lay members. The GDG identified relevant clinical questions, collected and appraised clinical evidence, and evaluated the cost effectiveness of proposed interventions where possible. A network meta-analysis was undertaken to identify the clinical effectiveness of different types of treatments for tocolysis which fitted the cost effectiveness analysis.

The draft guideline underwent a public consultation in which stakeholder organisations were invited to comment; the GDG then took all comments into consideration when producing the final version of the guideline. Four different versions of this guideline have been produced: a full version containing all the evidence, the process undertaken to develop the recommendations, and all the recommendations; a care pathway; a version containing a list of all the recommendations, known as the “Short guideline”; and a version for the public. All of these versions are available from the NICE website (www.nice.org.uk/guidance/ng25). Updates of the guideline will be produced as part of NICE’s guideline development programme.

Future research

1. For women with a short cervix and a history of spontaneous preterm birth, how effective is prophylactic cervical cerclage alone compared with prophylactic vaginal progesterone alone and with both strategies together, in preventing preterm birth?
2. What is the diagnostic accuracy of serial C reactive protein testing to identify chorioamnionitis in women with preterm prelabour membrane rupture?
3. For women at risk of preterm birth, what is the clinical effectiveness of rescue cerclage?
4. What is the clinical effectiveness of a bolus plus infusion of magnesium sulfate compared with a bolus alone for preventing neurodevelopmental injury in babies born preterm?